• ViroPharma Inc., of Exton, Pa., reported net product sales of $106.5 million for the fourth quarter, a decline compared to the fourth quarter of 2011, largely attributed to the loss of revenues due to generic competition to antibiotic drug Vancocin (vancomycin).